Overview

Sacubitril/Valsartan in Resistant Hypertension

Status:
Recruiting
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in patients with resistant hypertension compared to the use of recommended and optimized antihypertensive therapy, through a randomized clinical trial, over 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Geral Roberto Santos
Collaborator:
Hospital Universitário Professor Edgard Santos
Treatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination
Valsartan